CLEC4G and neoplasm: That is to say, in the future, targeted silencing of CLEC4G expression can not only reverse the drug resistance of HCC cells to Lenva but also further promote the death of tumor cells, thus providing a more reliable guarantee for the treatment and prognosis of HCC patients.